Total Valuation
TG Therapeutics has a market cap or net worth of CHF6.44B. The enterprise value is CHF5.56K.
Market CapCHF6.44B
Enterprise ValueCHF5.56K
Share Statistics
TG Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders7.54%
Owned by Institutions2.85%
Financial Efficiency
TG Therapeutics’s return on equity (ROE) is 0.69 and return on invested capital (ROIC) is 13.54%.
Return on Equity (ROE)0.69
Return on Assets (ROA)0.42
Return on Invested Capital (ROIC)13.54%
Return on Capital Employed (ROCE)0.14
Revenue Per Employee1.54M
Profits Per Employee1.12M
Employee Count399
Asset Turnover0.58
Inventory Turnover0.80
Valuation Ratios
The current PE Ratio of TG Therapeutics is 16.4. TG Therapeutics’s PEG ratio is 0.00523.
PE Ratio16.4
PS Ratio6.98
PB Ratio6.64
Price to Fair Value6.64
Price to FCF-172.18
Price to Operating Cash Flow395.59
PEG Ratio0.00523
Income Statement
In the last 12 months, TG Therapeutics had revenue of 616.29M and earned 447.18M in profits. Earnings per share was 3.10.
Revenue616.29M
Gross Profit515.57M
Operating Income123.32M
Pretax Income107.39M
Net Income447.18M
EBITDA134.36M
Earnings Per Share (EPS)3.10
Cash Flow
In the last 12 months, operating cash flow was -18.00K and capital expenditures -542.00K, giving a free cash flow of -560.00K billion.
Operating Cash Flow-18.00K
Free Cash Flow-560.00K
Free Cash Flow per Share-10.00T>
Dividends & Yields
TG Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta5.21
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
TG Therapeutics upcoming earnings date is Nov 9, 2026, TBA (Confirmed).
Last Earnings DateAug 3, 2026
Next Earnings DateNov 9, 2026
Ex-Dividend Date―
Financial Position
TG Therapeutics as a current ratio of 4.10, with Debt / Equity ratio of 1.50%
Current Ratio4.10
Quick Ratio3.29
Debt to Market Cap0.06
Net Debt to EBITDA1.35
Interest Coverage Ratio4.61
Taxes
In the past 12 months, TG Therapeutics has paid -339.79M in taxes.
Income Tax-339.79M
Effective Tax Rate-3.16
Enterprise Valuation
TG Therapeutics EV to EBITDA ratio is 33.37, with an EV/FCF ratio of -179.45.
EV to Sales7.28
EV to EBITDA33.37
EV to Free Cash Flow-179.45
EV to Operating Cash Flow-181.00
Balance Sheet
TG Therapeutics has CHF552.25M in cash and marketable securities with CHF754.44M in debt, giving a net cash position of -CHF202.19M billion.
Cash & Marketable SecuritiesCHF552.25M
Total DebtCHF754.44M
Net Cash-CHF202.19M
Net Cash Per Share-CHF10.00T>
Tangible Book Value Per ShareCHF4.49
Margins
Gross margin is 82.36%, with operating margin of 20.01%, and net profit margin of 72.56%.
Gross Margin82.36%
Operating Margin20.01%
Pretax Margin17.43%
Net Profit Margin72.56%
EBITDA Margin21.80%
EBIT Margin21.76%
Analyst Forecast
The average price target for TG Therapeutics is CHF51.71, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF51.71
Price Target Upside― Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast―